ArticleCancers2023
Estimating the Time Toxicity of Contemporary Systemic Treatment Regimens for Advanced Esophageal and Gastric Cancers.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Time toxicity in cancer care: a systematic review of definitions and measurement methods.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Time toxicity among patients with cancer: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Experiences and coping strategies of time toxicity in young and middle-aged patients with lymphoma: a descriptive qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Drinkable gene therapy foam for the treatment of constrictive esophageal carcinoma.Gene therapy · 2026Article
- A novel patient-centered outcome in cancer care, days at home: a scoping review and guide for its future use.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Toward Optimized Platinum Therapy: A Risk Prediction Model for Toxicity Based on Platinum Accumulation and Its Impact on Treatment Outcomes.Drug design, development and therapy · 2026Article
- Time-Toxicity Indicators and Mitigation Strategies in Cancer Care: A Scoping Review.Journal of multidisciplinary healthcare · 2026Review
- Amylin inhibits gastric cancer progression by targeting CCN1 and affecting the PI3K/AKT signalling pathway.Annals of medicine · 2025Article
- Time toxicity in previously untreated metastatic or unresectable epidermal growth factor receptor-mutant non-small cell lung cancer: a clinical practice review.Translational lung cancer research · 2025Review
- The weight of time: experience of time toxicity among advanced cancer patients and their family caregivers-a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Telehealth and Health Care Contact Days Among Patients With Advanced Cancer After COVID-19.JAMA network open · 2025Article
- Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience.Immunotherapy · 2025Article
- Implementation of a Traceback Testing Program for Ovarian Cancer: Findings from the FACTS Study.Cancers · 2025Article
- Trends in complexity of single-agent and combination therapies for solid tumor cancers approved by the US Food and Drug Administration.The oncologist · 2025Article
- Time toxicity in cancer care: A concept analysis using Walker and Avant's method.Asia-Pacific journal of oncology nursing · 2024Review
- Time's up: the urgency to investigate time toxicity in patients with genitourinary malignancies.Therapeutic advances in medical oncology · 2024Review
- Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms.Therapeutic advances in hematology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: The purpose of this study was to evaluate the time toxicity, or time spent in health care, of immunotherapy- versus chemotherapy-based regimens for metastatic esophageal and gastric cancers. (2) Methods: A literature search was conducted, and 18 phase III clinical trials of immune checkpoint inhibitors were selected for analysis. Health care days were calculated based on the number of days associated with receiving therapy and the adverse events reported in the clinical trials. Both the number of health care days and the median overall survival were compared among chemotherapy-only, immunotherapy-only, and chemo-immunotherapy regimens across this cohort of drug registration trials. (3) Results: The estimated median number of health care days was 37 (range of 7-52) days, or 1.2 (range of 0.2-1.7) months, compared to a median survival of 10.2 months across these 18 studies. For the chemotherapy-only regimens, the median number of health care days was 39 (range of 21-51) days, and for chemo-immunotherapy, it was 39 (range of 30-52) days. The immunotherapy-only regimens had fewer days, a median of 28 (range of 24-41),
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.